

VALUE-BASED CONTRACTS: 2009 – Q1 2018

This list includes value-based contracts (VBCs) executed and publicly announced in the United States from 2009 through the first quarter of 2018. This list is not comprehensive; many VBCs are executed without the release of publicly available information.

This list is current as of April 5, 2018.

	Brand Name	Non-Proprietary Name	Year	Therapeutic Area	Disease Area	Biopharmaceutical Company	Payer
1	Extampza ER	Oxycodone	2018	Opioids	Pain management	Collegium Pharmaceutical	Cigna
2	Jardiance	Empagliflozin	2018	Endocrinology	Diabetes	Boehringer Ingelheim	Prime Therapeutics
3	Luxturna	Voretigene Neparvovec-rzyl	2018	Ophthalmology	Retinal Disease	Spark Therapeutics	Harvard Pilgrim Health Care
4	Victoza	Liraglutide	2018	Endocrinology	Diabetes	Novo Nordisk	SelectHealth
5	Brilinta	Ticagrelor	2017	Cardiovascular Disease	Cardiovascular Disease	AstraZeneca	Harvard Pilgrim Health Care
6	Bydureon	Exenatide	2017	Endocrinology	Diabetes	AstraZeneca	Harvard Pilgrim Health Care
7	Enbrel	Etanercept	2017	Rheumatology	Rheumatoid Arthritis	Amgen	Harvard Pilgrim Health Care
8	Forteo	Teriparatide	2017	Musculoskeletal	Osteoporosis	Eli Lilly	Harvard Pilgrim Health Care
9	Janumet/Januvia	Sitagliptin/Metformin	2017	Endocrinology	Diabetes	Merck	Aetna
10	Kymriah	Tisagenlecleucel	2017	Oncology	Acute Lymphoblastic Leukemia	Novartis	Unspecified
11	Unspecified (MS)	Unspecified (MS)	2017	Neurology	Multiple Sclerosis	Biogen	SelectHealth
12	Unspecified (MS)	Unspecified (MS)	2017	Neurology	Multiple Sclerosis	Biogen	Harvard Pilgrim
13	Unspecified (MS)	Unspecified (MS)	2017	Neurology	Multiple Sclerosis	Biogen	Moda Health
14	Unspecified (MS)	Unspecified (MS)	2017	Neurology	Multiple Sclerosis	Biogen	Abarca Health
15	Victoza	Liraglutide	2017	Endocrinology	Diabetes	Novo Nordisk	Humana
16	Effient	Prasugrel	2016	Cardiology	Cardiovascular Disease	Eli Lilly	Humana
17	Entresto	Sacubitril and Valsartan	2016	Cardiology	Heart Failure	Novartis	Cigna
18	Entresto	Sacubitril and Valsartan	2016	Cardiology	Heart Failure	Novartis	Aetna
19	Entresto	Sacubitril and Valsartan	2016	Cardiology	Heart Failure	Novartis	Harvard Pilgrim Health Care

VALUE-BASED CONTRACTS: 2009 – Q1 2018

This list includes value-based contracts (VBCs) executed and publicly announced in the United States from 2009 through the first quarter of 2018. This list is not comprehensive; many VBCs are executed without the release of publicly available information.

This list is current as of April 5, 2018.

20	Praluent	Alirocumab	2016	Cardiology	Hypercholesterolemia	Sanofi, Regeneron	Cigna
21	Repatha	Evolocumab	2016	Cardiology	Hypercholesterolemia	Amgen	Cigna
22	Trulicity	Dulaglutide	2016	Endocrinology	Diabetes	Eli Lilly	Harvard Pilgrim Health Care
23	Avastin	Bevacizumab	2015	Oncology	Non-small-cell Lung Cancer (NSCLC)	Genentech	Priority Health
24	Brilinta	Ticagrelor	2015	Cardiovascular Disease	Cardiovascular Disease	AstraZeneca	University of Pittsburgh Medical Center
25	Harvoni	Ledipasvir-sofosbuvir	2015	Infectious Diseases	Hepatitis C	Gilead	Cigna
26	Harvoni	Ledipasvir-sofosbuvir	2015	Infectious Diseases	Hepatitis C	Gilead	Optum
27	Iressa	Gefitinib	2015	Oncology	Lung Cancer	AstraZeneca	Express Scripts
28	Praluent	Alirocumab	2015	Endocrinology	Familial Hypercholesterolemia	Sanofi, Regeneron	Prime Therapeutics
29	Repatha	Evolocumab	2015	Endocrinology	Familial Hypercholesterolemia	Amgen	Harvard Pilgrim Health Care
30	Repatha	Evolocumab	2015	Endocrinology	Familial Hypercholesterolemia	Amgen	Prime Therapeutics
31	Repatha	Evolocumab	2015	Cardiology	Hypercholesterolemia	Amgen	CVS Health
32	Viekira Pak	Dasabuvir, Ombitasvir, Paritaprevir, and Ritonavir	2015	Infectious Diseases	Hepatitis C	AbbVie	Express Scripts
33	Rebif	Interferon Beta-1a	2012	Neurology	Multiple Sclerosis	EMD Serono	Prime Therapeutics
34	Actonel	Risedronate	2011	Endocrinology	Osteoporosis	Warner Chilcott	Prime Therapeutics
35	Betaseron	Interferon Beta-1b	2011	Neurology	Multiple Sclerosis	Bayer HealthCare Pharmaceuticals	Health Alliance Medical Plans, Inc.
36	Januvia	Sitagliptin	2011	Endocrinology	Diabetes	Merck	Prime Therapeutics
37	Rebif	Interferon Beta-1a	2011	Neurology	Multiple Sclerosis	EMD Serono	Cigna
38	Actonel	Risedronate	2009	Endocrinology	Osteoporosis	Proctor and Gamble	Health Alliance
39	Janumet/Januvia	Metformin/Sitagliptin	2009	Endocrinology	Diabetes	Merck	Cigna